BioNano Genomics has completed a $53 million Series C financing co-led by Legend Capital and Novartis Venture Fund. The round came with a $109 million valuation. Proceeds from the funding will be used to expand commercialization efforts to grow the installed base and utilization of BioNano's Irys platform and for further technology innovations. Irys enables the detection of structural variations in the human genome in order to create more personalized medicine and diagnostics. The company last raised funds in a 2012 B1 round, receiving about $11.6 million at a valuation of $51 million, more than 4x larger than the $11.7 million valuation it received with its $5 million Series A round in 2008.